Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kangbaida (Sichuan) Biotechnology Co. Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The profile spans 2 distinct examiners and 2 distinct art units. RODRIGUEZ-GARCIA, VALERIE is the named busiest examiner, with 1 pending action.
The split allocation calls for matter-by-matter prosecution management. Counsel should track examiner positions independently while maintaining consistent disclosure and claim terminology across the biotechnology portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.7% |
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18710500 | Selective Parp1 Inhibitor And Application Thereof | RODRIGUEZ-GARCIA, VALERIE | — |
| 18694646 | CRYSTAL FORM OF IMIDAZOLINONE DERIVATIVE | GONZALEZ, LUISALBERTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18710500 | Selective Parp1 Inhibitor And Application Thereof | RODRIGUEZ-GARCIA, VALERIE | — |
| 18694646 | CRYSTAL FORM OF IMIDAZOLINONE DERIVATIVE | GONZALEZ, LUISALBERTO | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18710500 | Selective Parp1 Inhibitor And Application Thereof | RODRIGUEZ-GARCIA, VALERIE | 1621 | §102§103§112 | Non-Final OA | — | Pending | May 15, 2024 |
| 18694646 | CRYSTAL FORM OF IMIDAZOLINONE DERIVATIVE | GONZALEZ, LUISALBERTO | 1624 | §103§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKangbaida (Sichuan) Biotechnology Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Valerie Rodriguez-Garcia has the most, with 1 of Kangbaida (Sichuan) Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
